XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 151 filers reported holding XENON PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 3.19 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $79,388 | -19.2% | 2,324 | -8.9% | 0.05% | -17.2% |
| Q2 2023 | $98,252 | +5.2% | 2,552 | -2.2% | 0.06% | +13.7% |
| Q1 2023 | $93,412 | -34.5% | 2,610 | -27.8% | 0.05% | -31.1% |
| Q4 2022 | $142,579 | +7.2% | 3,616 | -1.6% | 0.07% | +39.6% |
| Q3 2022 | $133,000 | +19.8% | 3,673 | +0.8% | 0.05% | +29.3% |
| Q2 2022 | $111,000 | -40.3% | 3,643 | -40.1% | 0.04% | -50.6% |
| Q1 2022 | $186,000 | -7.5% | 6,078 | -5.6% | 0.08% | +9.2% |
| Q4 2021 | $201,000 | +14.2% | 6,439 | -44.0% | 0.08% | -1.3% |
| Q3 2021 | $176,000 | -21.8% | 11,494 | -4.9% | 0.08% | -17.2% |
| Q2 2021 | $225,000 | -49.3% | 12,091 | -51.3% | 0.09% | -50.5% |
| Q1 2021 | $444,000 | +18.4% | 24,819 | +1.8% | 0.19% | +20.5% |
| Q4 2020 | $375,000 | +32.0% | 24,381 | -5.0% | 0.16% | +4.7% |
| Q3 2020 | $284,000 | -22.4% | 25,673 | -12.0% | 0.15% | -13.9% |
| Q2 2020 | $366,000 | – | 29,170 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ghost Tree Capital, LLC | 850,000 | $15,215,000 | 3.58% |
| ACUTA CAPITAL PARTNERS, LLC | 412,500 | $7,384,000 | 2.66% |
| BVF INC/IL | 3,481,778 | $62,324,000 | 2.34% |
| Soleus Capital Management, L.P. | 708,117 | $12,675,000 | 2.28% |
| COMMODORE CAPITAL LP | 301,392 | $5,395,000 | 2.15% |
| DAFNA Capital Management LLC | 406,535 | $7,277,000 | 1.73% |
| Parkman Healthcare Partners LLC | 374,395 | $6,702,000 | 1.56% |
| Avoro Capital Advisors LLC | 3,650,000 | $65,335,000 | 1.13% |
| KNOTT DAVID M | 144,101 | $2,579,000 | 1.10% |
| Orbimed Advisors | 2,497,917 | $44,713,000 | 0.42% |